➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Merck
Moodys
Baxter

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Apotex Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for APOTEX, and what generic and branded alternatives to APOTEX drugs are available?

APOTEX has two hundred and sixty-seven approved drugs.

There are twenty-three tentative approvals on APOTEX drugs.

Drugs and US Patents for Apotex

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc CARBAMAZEPINE carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 078986-001 Nov 25, 2011 AB RX No No   Start Trial   Start Trial
Apotex Inc MONTELUKAST SODIUM montelukast sodium TABLET, CHEWABLE;ORAL 201508-001 Aug 3, 2012 DISCN No No   Start Trial   Start Trial
Apotex FAMOTIDINE famotidine TABLET;ORAL 075611-002 Jul 23, 2001 AB RX No No   Start Trial   Start Trial
Apotex Inc RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 091072-001 May 16, 2013 AB RX No No   Start Trial   Start Trial
Apotex Inc CEFPROZIL cefprozil TABLET;ORAL 065327-001 Mar 26, 2008 AB RX No No   Start Trial   Start Trial
Apotex AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE amlodipine besylate; benazepril hydrochloride CAPSULE;ORAL 091431-005 Dec 30, 2013 AB RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Apotex

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-003 Dec 29, 1992 6,172,233*PED   Start Trial
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 5,789,449*PED   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride TABLET;ORAL 020031-002 Dec 29, 1992 5,900,423*PED   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride SUSPENSION;ORAL 020710-001 Jun 25, 1997 5,900,423*PED   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride CAPSULE;ORAL 020885-004 Oct 9, 1998 6,133,289*PED   Start Trial
Apotex Technologies PAXIL paroxetine hydrochloride SUSPENSION;ORAL 020710-001 Jun 25, 1997 6,080,759*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for APOTEX drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2005-09-09
➤ Subscribe Oral Suspension 10 mg/5 mL ➤ Subscribe 2005-02-10
➤ Subscribe Extended-release Tablets 37.5 mg ➤ Subscribe 2009-05-19
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
McKinsey
Colorcon
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.